1. Dabrafenib monotherapy for a recurrent BRAFV600E-mutated TTF-1-positive posterior pituitary tumor
- Author
-
Flavie Grenier-Chartrand, Sami Barrit, Marie Lucie Racu, Sylvie Luce, Julien Spitaels, Niloufar Sadeghi-Meibodi, Laetitia Lebrun, Isabelle Salmon, Florence Lefranc, and Olivier De Witte
- Subjects
Proto-Oncogene Proteins B-raf ,Mutation ,Oximes ,Thyroid Nuclear Factor 1 ,Imidazoles ,Humans ,Female ,Pituitary Neoplasms ,Surgery ,Neurology (clinical) ,Middle Aged ,Protein Kinase Inhibitors - Abstract
Posterior pituitary tumors (PPT) expressing thyroid transcription factor-1 (TTF-1) are extremely rare low-grade neoplasms. The recent discovery of BRAF mutations in these tumors offers a potential alternative treatment using targeted therapies. We present the case of a 57-year-old female with recurrent BRAFV600E-mutated TTF-1-positive PPT treated with a BRAF inhibitor monotherapy (dabrafenib) leading to tumor regression. After 18 months of uninterrupted treatment, ongoing radiological tumor regression was observed and the patient remained asymptomatic without any significant adverse event. BRAF inhibitor is potentially a valuable treatment option for recurrent TTF-1-positive PPT with BRAF mutation.
- Published
- 2022